Vol 6, No 3-4 (2012)
- Year: 2012
- Published: 15.10.2012
- Articles: 15
- URL: https://klinitsist.abvpress.ru/Klin/issue/view/5
EDITORIAL
Using Registers to Study Effectiveness and Safety of Drugs
Abstract
The article discusses the main aspects of registers use to evaluate the effectiveness and safety of drugs. It is noted that the results of the randomized clinical trials are currently constitute the highest level of evidence in medicine, but they have several limitations. Besides, in many
cases evidence based on the results of the randomized clinical trials (RCTs) is simply missing. In this connection need for observational studies that, despite some limitations often supplement the information obtained in the RCT is discussed. Registers as the way to study the effectiveness and safety of drugs could help overcome some limitations of observational studies. The examples of both Russian and foreign studies held within registers in order to study the effectiveness of drugs in cardiology are provided. The framework for RCTs and registries contribution in studying effectiveness and safety of a drug is proposed.
4-9
ORIGINAL INVESTIGATIONS
Possibilities for the early detection of hypertensive disease in pregnant women
Abstract
Objective: to evaluate morphofunctional changes in the cardiovascular system of pregnant women with arterial hypertension (AH) to detect
chronic AH - hypertensive disease.
Subjects and methods. 126 pregnant women with AH (at 28–34 weeks gestation; mean age 26.1 ± 1.7 years) were examined. All the pregnant
women underwent assessment of risk factors for AH, double measurement of office blood pressure, 24-hour blood pressure monitoring, electrocardiography, carotid ultrasonography, a microalbumin urine test, and eyeground examination. The pattern of AH was specified 12 weeks after childbirth.
Results. Chronic AH – hypertensive disease – was diagnosed in 51 % of the examined pregnant women with AH. There was a considerable spread of risk factors for AH in this patient group. 26 % of them were found to have lesions of target organs (heart and/or arterial vessels); the rate of microalbuminuria registration was 41 %.
Conclusion. Among our examined group of pregnant patients with AH, the prevalence of hypertensive disease is 51 %. In the identified patient
group, cardiac and arterial vascular changes that could be considered as target organ lesions were found in almost a third of cases. Pregnant women with AH need to be meticulously examined and followed up by a therapist and a cardiologist in the postpartum period.
23-27
Diagnostic value of placental growth factor in patients with coronary heart disease
Abstract
Objective: to study the diagnostic value of placental growth factor (PlGF) in patients with coronary heart disease (CHD).
Subjects and methods. 151 patients (75 men and 76 women; mean age 58.9 ± 12.3 years), including 66 patients with exercise-induced stable angina, 32 with unstable angina, 32 with myocardial infarction, and 21 with no clinical signs of CHD), were followed up. Blood PlGF levels were measured in all the examinees; C-reactive protein (CRP) concentrations were also determined using a high-sensitivity method in the patients with CHD.
Results. In the patients with acute coronary syndrome (ACS), the levels of PlGF were significantly higher than in those with exercise-induced stable angina and in healthy individuals (17.3 ± 11.4 versus 11.2 ± 7.3 and 8.8 ± 6.7 pg/ml; p < 0.001). Estimation of the diagnostic value of the determination of PlGF levels in the diagnosis of ACS in troponin-negative examinees revealed that the area under the ROC curve (AUC) was 0.76. The quality of a diagnostic model using CRP was inferior to that with PlGF (n = 45; AUC for PlGF = 0.79; that for CRP = 0.65).
Conclusion. The elevated level of PlGF may be considered as a diagnostic marker for ACS, including in the absence of the higher levels of cardiac troponins.
28-32




